Perrigo PE Ratio 2010-2024 | PRGO
Current and historical p/e ratio for Perrigo (PRGO) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Perrigo PE ratio as of April 21, 2025 is 9.89.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Perrigo PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-04-21 | 24.36 | 0.00 | |
| 2024-12-31 | 25.45 | $-1.25 | 0.00 |
| 2024-09-30 | 25.72 | $-1.17 | 0.00 |
| 2024-06-30 | 24.94 | $-0.92 | 0.00 |
| 2024-03-31 | 30.95 | $-0.07 | 0.00 |
| 2023-12-31 | 30.63 | $-0.10 | 0.00 |
| 2023-09-30 | 30.14 | $0.05 | 602.80 |
| 2023-06-30 | 31.78 | $-0.42 | 0.00 |
| 2023-03-31 | 33.29 | $-0.96 | 0.00 |
| 2022-12-31 | 31.41 | $-0.96 | 0.00 |
| 2022-09-30 | 32.59 | $-0.63 | 0.00 |
| 2022-06-30 | 36.82 | $-0.70 | 0.00 |
| 2022-03-31 | 34.65 | $-0.65 | 0.00 |
| 2021-12-31 | 34.81 | $-0.35 | 0.00 |
| 2021-09-30 | 42.07 | $-1.88 | 0.00 |
| 2021-06-30 | 40.52 | $-2.57 | 0.00 |
| 2021-03-31 | 35.58 | $-1.70 | 0.00 |
| 2020-12-31 | 39.09 | $-1.21 | 0.00 |
| 2020-09-30 | 39.95 | $-0.06 | 0.00 |
| 2020-06-30 | 47.89 | $1.74 | 27.52 |
| 2020-03-31 | 41.50 | $1.37 | 30.29 |
| 2019-12-31 | 44.41 | $1.07 | 41.51 |
| 2019-09-30 | 47.85 | $1.81 | 26.43 |
| 2019-06-30 | 40.58 | $0.65 | 62.44 |
| 2019-03-31 | 40.85 | $0.84 | 48.64 |
| 2018-12-31 | 32.74 | $0.94 | 34.83 |
| 2018-09-30 | 59.64 | $0.86 | 69.35 |
| 2018-06-30 | 61.26 | $1.66 | 36.90 |
| 2018-03-31 | 69.85 | $0.91 | 76.76 |
| 2017-12-31 | 72.88 | $0.84 | 86.76 |
| 2017-09-30 | 70.65 | $-9.16 | 0.00 |
| 2017-06-30 | 62.90 | $-18.23 | 0.00 |
| 2017-03-31 | 55.18 | $-16.39 | 0.00 |
| 2016-12-31 | 69.02 | $-19.23 | 0.00 |
| 2016-09-30 | 76.45 | $-10.49 | 0.00 |
| 2016-06-30 | 74.95 | $-0.96 | 0.00 |
| 2016-03-31 | 105.60 | $-1.93 | 0.00 |
| 2015-12-31 | 119.30 | $-0.26 | 0.00 |
| 2015-09-30 | 129.55 | $0.99 | 130.86 |
| 2015-06-30 | 152.15 | $0.94 | 161.86 |
| 2015-03-31 | 136.19 | $0.56 | 243.20 |
| 2014-12-31 | 137.41 | $1.59 | 86.42 |
| 2014-09-30 | 123.37 | $0.21 | 587.49 |
| 2014-06-30 | 119.65 | $0.67 | 178.58 |
| 2014-03-31 | 126.86 | $0.67 | 189.34 |
| 2013-12-31 | 125.79 | $1.49 | 84.42 |
| 2013-09-30 | 101.07 | $3.48 | 29.04 |
| 2013-06-30 | 99.04 | $3.42 | 28.96 |
| 2013-03-31 | 97.12 | $3.42 | 28.40 |
| 2012-12-31 | 85.02 | $3.47 | 24.50 |
| 2012-09-30 | 94.86 | $3.41 | 27.82 |
| 2012-06-30 | 96.23 | $3.04 | 31.65 |
| 2012-03-31 | 84.23 | $3.04 | 27.71 |
| 2011-12-31 | 79.27 | $2.76 | 28.72 |
| 2011-09-30 | 79.04 | $2.67 | 29.60 |
| 2011-06-30 | 71.47 | $2.72 | 26.27 |
| 2011-03-31 | 64.62 | $2.72 | 23.76 |
| 2010-12-31 | 51.42 | $2.43 | 21.16 |
| 2010-09-30 | 52.08 | $2.01 | 25.91 |
| 2010-06-30 | 47.85 | $1.87 | 25.59 |
| 2010-03-31 | 47.52 | $1.87 | 25.41 |
| 2009-12-31 | 32.19 | $1.70 | 18.93 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.455B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $227.162B | 27.40 |
| Boston Scientific (BSX) | United States | $140.689B | 37.90 |
| Stryker (SYK) | United States | $132.255B | 28.42 |
| EssilorLuxottica (ESLOY) | France | $128.431B | 0.00 |
| Medtronic (MDT) | Ireland | $105.938B | 15.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.424B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.151B | 26.20 |
| ResMed (RMD) | United States | $31.269B | 24.08 |
| Agilent Technologies (A) | United States | $29.217B | 19.30 |
| GE HealthCare Technologies (GEHC) | United States | $28.556B | 13.89 |
| Terumo (TRUMY) | Japan | $28.160B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.192B | 15.85 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.373B | 12.24 |
| Insulet (PODD) | United States | $17.332B | 74.11 |
| Baxter (BAX) | United States | $14.818B | 10.66 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.356B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $7.609B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.938B | 17.06 |
| Bio-Rad Laboratories (BIO) | United States | $6.672B | 23.10 |
| Demant (WILYY) | Denmark | $6.644B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.977B | 18.98 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.400B | 29.07 |
| Haemonetics (HAE) | United States | $2.872B | 13.52 |
| Envista Holdings (NVST) | United States | $2.614B | 20.80 |
| GN Store Nord (GNNDY) | Denmark | $2.188B | 14.75 |
| LeMaitre Vascular (LMAT) | United States | $1.946B | 44.47 |
| QuidelOrtho (QDEL) | United States | $1.698B | 14.22 |
| AtriCure (ATRC) | United States | $1.565B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.214B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.189B | 18.67 |
| AdaptHealth (AHCO) | United States | $1.051B | 10.12 |
| BioLife Solutions (BLFS) | United States | $1.041B | 0.00 |
| InMode (INMD) | Israel | $1.038B | 8.67 |
| Neogen (NEOG) | United States | $0.953B | 12.19 |
| Phibro Animal Health (PAHC) | United States | $0.700B | 10.74 |
| Evolus (EOLS) | United States | $0.686B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.649B | 0.00 |
| Valneva SE (VALN) | France | $0.552B | 0.00 |
| Owens & Minor (OMI) | United States | $0.535B | 4.56 |
| CeriBell (CBLL) | United States | $0.532B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.514B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.453B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.450B | 0.00 |
| Surmodics (SRDX) | United States | $0.394B | 0.00 |
| Omeros (OMER) | United States | $0.394B | 0.00 |
| SNDL (SNDL) | Canada | $0.368B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.328B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.302B | 13.07 |
| Viemed Healthcare (VMD) | United States | $0.262B | 23.68 |
| Sanara MedTech (SMTI) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 15.65 |
| Sanuwave Health (SNWV) | United States | $0.256B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.251B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.250B | 44.40 |
| Cerus (CERS) | United States | $0.242B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.224B | 0.00 |
| Quanterix (QTRX) | United States | $0.200B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.189B | 0.00 |
| High Tide (HITI) | Canada | $0.187B | 0.00 |
| Biote (BTMD) | United States | $0.181B | 4.12 |
| TriSalus Life Sciences (TLSI) | United States | $0.175B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.172B | 13.24 |
| Brainsway (BWAY) | Israel | $0.155B | 48.47 |
| Jin Medical (ZJYL) | China | $0.147B | 0.00 |
| Organigram Global (OGI) | Canada | $0.135B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.123B | 15.42 |
| Agape ATP (ATPC) | $0.094B | 0.00 | |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.086B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.083B | 0.00 |
| Exagen (XGN) | United States | $0.080B | 0.00 |
| MacroGenics (MGNX) | United States | $0.079B | 0.00 |
| Veru (VERU) | United States | $0.078B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.65 |
| Zynex (ZYXI) | United States | $0.066B | 24.22 |
| United Health Products (UEEC) | United States | $0.065B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 11.61 |
| Apyx Medical (APYX) | United States | $0.037B | 0.00 |
| Modular Medical (MODD) | United States | $0.036B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.035B | 51.50 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.010B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |